Pegaspargase 3,750unit powder for solution for injection vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Pegaspargase
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Pegaspargase
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Pegaspargase
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Pegaspargase on the MHRA register
Oncaspar 3,750unit powder for solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (TA1049)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · Randomised trials: 3 · 2017–2025
Showing the 50 most relevant studies, sorted by most relevant.
Feng D, Yan Z, Fu B, et al.
2024
- Polyethylene Glycols
- Etoposide
- Asparaginase
M. Strullu, Arnaud Petit, C. Halfon-Domenech, et al.
Blood, 2024
Young-A. Heo, Yahiya Y. Syed, S. Keam
Drugs, 2019
Manjunath Nookala Krishnamurthy, Gaurav Narula, Khushboo Gandhi, et al.
JCO Global Oncology, 2020
Grace Baek, Miryoung Kim, Madison Lee, et al.
Journal of Oncology Pharmacy Practice, 2024
- Lymphoma, T-Cell
- Polyethylene Glycols
- Asparaginase
Chenhong Jia, Qian Li, Xiaoying Zhai, et al.
Journal of Cancer Research and Clinical Oncology, 2025
- Pancreatitis
- Polyethylene Glycols
- Asparaginase
McCarty K, Smith C, Zhang S, et al.
2025
- Drug Hypersensitivity
- Polyethylene Glycols
- Asparaginase
Nadeem S, Elahi E, Iftikhar I, et al.
2024
Acute lymphoblastic leukemia (ALL) during pregnancy necessitates treatment with high-dose chemotherapy, which can threaten the lives of both the mother and fetus. The aim of the treatment not only focuses on selecting and administering optimal chemotherapy with appropriate doses to the mother but also reflects the crucial understanding of the fetal gestational age at the time of administration of chemotherapy to minimize fetal exposure. We describe the case of a 19-year-old patient diagnosed with ALL at 29 weeks gestation. She received treatment in the third trimester with the Berlin-Frankfurt-Munster (BFM) 2000 induction chemotherapy protocol consisting of a combination of daunorubicin, vincristine, pegaspargase, prednisolone, and intrathecal (IT) methotrexate and gave birth to a healthy baby girl via vaginal delivery four weeks after initiating the induction of chemotherapy.
Abstract licence: CC BY
E. Boychenko, A. Islamova, D. K. Senova, et al.
Pediatric Hematology/Oncology and Immunopathology, 2025
A. Caprara, J. Rissardo, V. Byroju
Neurology, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5.8 days
Mechanism
Pegaspargase is a pegylated L-asparaginase that catalyzes the conversion of the…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
82%
Half-life
5.8 days
Volume of distribution
1.86 L
Metabolism
Since…
Elimination
[L44672]
Clearance
0.17 L
[L44667]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Pegaspargase has the same mechanism of action as [L-asparaginase] derived from Escherichia coli, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from Escherichia coli may cause hypersensitivity in some patients and require frequent administration. The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase.[A255912][A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
[L44667]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 453 interactions
The carcinogenic, mutagenic and fertility effects of pegaspargase have not been evaluated.
[L44667]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L44667]
The Tmax for these patients was 1.25 hr.
[L44672]
The impact of renal and hepatic impairment on pegaspargase pharmacokinetics is unknown.
[L44667]
[L44667]
[L44667]
Since these enzymes are ubiquitously distributed, the exact role of the liver is unknown.
[L44672]
[L44672]
[L44667]
Proteins that carry this drug through the body
ATC L01XX24
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Pegaspargase
Additional database identifiers
Drugs Product Database (DPD)
11706
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11583
GenAtlas
SERPINA7
GeneCards
SERPINA7
GenBank Gene Database
M14091
GenBank Protein Database
338697
UniProt Accession
THBG_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72